Client Spotlight: Ablynx

October 2, 2018

John R. Van Amsterdam PhD

Wolf Greenfield is fortunate to work with clients across industries that are leaders in their fields. To highlight the work they are doing and the ways in which we work together, we feature client spotlights in the form of case studies.

In this case study, we profile Ablynx. Ablynx is developing a new class of drugs that combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs, and judging by the reception in the market, this technology is in high demand.

CLICK HERE TO VIEW THE CASE STUDY